SCHEMBL27085652

SCHEMBL27085652

COc1ccc(CN2C(=O)CCC(n3c4cc(Cl)ccc4c4cccnc43)C2=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 5/20 0.55
▸ CRBN Q96SW2 5/20 0.55
▸ MAPT P10636 4/20 0.43
▸ THRB P10828 2/20 0.43
▸ MAT2A P31153 1/20 0.42
▸ RXFP1 Q9HBX9 2/20 0.39
▸ MDM2 Q00987 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PTGDR2 Q9Y5Y4 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27085646 0.91 DDB1 (0.54) DDB1CRBNMAPTTHRBRXFP1
SCHEMBL23319581 0.90 MAPT (0.42) DDB1CRBNMAPTTHRBALDH1A1
SCHEMBL23319541 0.89 DDB1 (0.46) DDB1CRBNMAPTTHRBRXFP1
SCHEMBL21069724 0.88 DDB1 (0.42) DDB1CRBNMAPTTHRBRXFP1
SCHEMBL31577865 0.88 DDB1 (0.42) DDB1CRBNMAPTTHRBRXFP1
SCHEMBL29945240 0.87 DDB1 (0.44) DDB1CRBNMAPTTHRBMAT2A
SCHEMBL23319554 0.87 DDB1 (0.44) DDB1CRBNMAPTTHRBMAT2A
SCHEMBL21070560 0.85 DDB1 (0.46) DDB1CRBNMAPTTHRBRXFP1
SCHEMBL21071141 0.83 ACHE (0.40) DDB1CRBNMAPTTHRBL3MBTL1
SCHEMBL21070398 0.82 MAPT (0.41) DDB1CRBNMAPTTHRBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250042902-A1 TRICYCLIC CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-06 — — US disclosed
US-11897882-B2 Tricyclic crbn ligands and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-02-13 — — US disclosed
US-20220306631-A1 TRICYCLIC CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-09-29 — — US disclosed
US-11292792-B2 Tricyclic CRBN ligands and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11292792-B2 Tricyclic CRBN ligands and uses thereof CRBN, CRKL, CUL4A DDB1 92/4885CRBN 1/4885MAPT 1069/4885
US-11897882-B2 Tricyclic crbn ligands and uses thereof CRBN, CRKL, CUL4A DDB1 92/4885CRBN 1/4885MAPT 1069/4885
US-20250042902-A1 TRICYCLIC CRBN LIGANDS AND USES THEREOF CRBN, CRKL, CUL4A DDB1 92/4885CRBN 1/4885MAPT 1069/4885
US-20220306631-A1 TRICYCLIC CRBN LIGANDS AND USES THEREOF CRBN, CRKL, CUL4A DDB1 92/4885CRBN 1/4885MAPT 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback